# A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

> **NCT05607693** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** SHR3680 tablets

## Key facts

- **NCT ID:** NCT05607693
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-26
- **Primary completion:** 2024-11-05
- **Final completion:** 2024-11-05
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607693, "A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05607693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*